Home > Haematology > EHA 2019 > Myeloid Malignancies > Overcoming the “don’t eat me” signal in AML and MDS

Overcoming the “don’t eat me” signal in AML and MDS

Presented By
Dr David Sallman, Moffitt Cancer Center, USA
Conference
EHA 2019
Trial
5F9005
Antileukaemic activity was observed with anti-CD47 macrophage checkpoint inhibitor 5F9, both as monotherapy and in combination with azacytidine, in patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), as presented by Dr David Sallman (Moffitt Cancer Center, USA) [1]. 5F9 is a novel form of immunotherapy that targets CD47 to restore innate immunity, the first line of defence against cancer cells. CD47 provides the notorious “don’t eat me” signal displayed by many types of cancer cells that enables macrophage immune evasion by preventing phagocytosis. CD47 is the dominant macrophage checkpoint that is overexpressed in most cancer cells, and increased CD47 expression has been associated with poorer prognosis. In addition, azacitidine can upregulate the pro “eat-me” signals, and in an aggressive AML xenograft preclinical model, the combination of 5F9 and azacitidine significantly improved overall survival vs either azacitidine or 5F9...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on